A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer

Status:	Completed
Conditions:	Ovarian Cancer, Cancer, Cancer, Cancer, Cancer, Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	21 - Any
Updated:	9/19/2018
Start Date:	March 2006
End Date:	October 2010

This Study is a Non-randomized, Open-label, Multi-center Phase II Study of GW786034 to Evaluate the Administration of Oral GW786034 in Subjects With Ovarian Cancer.

This study was designed to find out how effective and safe GW786034, is in the treatment of
epithelial ovarian, fallopian tube, or primary peritoneal cancer that has not responded to
standard treatment.

Inclusion criteria:

- Confirmed diagnosis of epithelial ovarian, fallopian tube or primary peritoneal
carcinoma.

- Has received one prior platinum-based chemotherapy regimen(cisplatin,carboplatin, or
oxaliplatin).

- Has psychological, familial, sociological or geographical condition that does not
permit compliance with the protocol.

- Is on a specifically prohibited medication or requires these medications during
treatment with GW786034.

Exclusion criteria:

- Has had any surgery, chemotherapy, hormonal therapy, biologic, immunotherapy, or
radiotherapy with in the last 28 days and has not recovered from such prior therapy.

- Poorly controlled hypertension(systolic 140mmHg or higher or Diastolic 90mmHg or
higher).

- Currently taking warfarin.

- Low molecular weight heparin and low-dose warfarin(1mg per day)is permitted.

We found this trial at

sites

GSK Investigational Site

Randwick, New South Wales 2031

from

Randwick,